

	(19) (12)	(KR) (B1)	(45) (11) (24)	2010 04 16 10-0953483 2010 04 09
(51)	Int. Cl.		(73)	
	<i>A61K 31/525</i> (2006 01) <i>A61K 31/198</i> (2006 01)			, , 77055, , 200,
(21)	10-2004-7007754			9432
(22)	() 2002 11 21		(72)	
	2007 11 14			
(85)	2004 05 21			, , , 77055, , 200,
(65)	10-2004-0065565			9432
(43)	2004 07 22			
(86)	PCT/US2002/037354		(74)	
(87)	W0 2003/045372			
	2003 06 05			
(30)	09/995, 010 2001 11 27 (US)			
(56)	US05817695 A1*			
	*			
	: 12			:
(54)				
(57)				

1

2

3

4

5

6

7

8

9

10

11

12

13

;

;

1~90ng/nL , 5~300ng/L, 2~120ng/nL,
0.5~30ng/nL , 1~75ng/nL , 1~75ng/nL ,
1~90ng/nL , 1~90ng/nL , 1~50ng/nL

14

13

15

13

16

13

6.0-7.0 pH

17

13

18

13

19

13

20

18

19

(enterally)

21

18

19

22

;

;

; 3-

-2.6-

23

22

1-15 %

25-75 %

,

3-

0.01-10 %

,

,

-2.6-

, 1-15 %

, 1-15 %

, 1-15 %

1-15 %

, 1-15 %

24

25

26

27

22

23

28

29

30

31

[0001]

[0002]

[0003]

(gastrointestinal tract epithelium) (self-renewing cell population) (antineoplastic)

(Vachon, ML S. et al., *J. Pain Symptom Management*, 10, 142-150 (1995); Coyle, N et al., *J. Pain Symptom Management*, 5, 83-93 (1990)).

Brietbart, W et al. (*Psychosomatics*, 33, 352-356 (1992))

Cope et al.

5,547,927 /

, b- , n-6 n-3 1.3:1 2.5:1

Pellico 5,817,695 , L- , L- L-

Chang et al. EP 0 747 395 A1

(aid)

Ozeki

GB 2 029 220 A

[0004]

(total parenteral nutrition, TPN

TPN

TPN

(Koretz, R.L. *J. Clinical Oncology*, 2: 534-538 (1984); McGeer, A.J.; Detsky, A.S.; O'Rourke, K. *Ann Internal Med*, 110: 734-736 (1989)). TPN

TPN

TPN

(exogenous substrate)

TPN

[0005]

(sugar),

(nucleobase)

(cancer cell line)

[0006]

(analogue)

TPN

A B C D

[0007]

[0008]

(urea cycle)

[0009]

(effector)

[0010]

(free)

6

; L-

, L-

L-

[0011]

[0012]

[0013]

[0014]

A _____

[0015]

(_____, _____, Inc. Gardena, CA)

(Yoneda, F _____, J. Chem Soc., Perkin Trans. I, 348(1978); U.S. Pat. No. 2,807,611).

[0016]

(U.S. Pat. No. 6,150,364; U.S. Pat. No. 5,589,355).

(_____, Kyowa Hakko Kogyo Co., LTD, Tokyo, Japan),

_____ a-

L- (levorotatory)

L-

[0017]

[0018]

[0019]

" "

[0020]

[0021]

/ _____ / _____

[0022]

" "

[0023]

" "

[0024]

" " " "

(a)

(b)

(packets), _____, _____ (teaspoonfuls), _____, _____, I.V., _____ (multiples)

[0025]

()

, L- (L-) 50 300
 0.1 3.0

[0026]

(AVA)
 (AVB)

, AVA AVB

[0027]

AVA	
	(g/L)
L-	4.46
	5.25
L-	5.25
	1.88
L-	5.96
L-	3.51
L-	8.71
(B ₂)	0.05
AVB	
	(g/L)
L-	4.46
	5.25
L-	5.25
	1.88
L-	5.96
L-	3.87
L-	8.71
(B ₂)	0.05

[0028]

AVA , 500 : 1 L-
 L- 2ng/mL 120ng/mL ,
 5-300ng/L . 1ng/mL 90ng/mL L- 1
 : 1 L- , L- L- ; 1ng/mL 75ng/mL L-
 1.4 : 1 ; 0.5ng/mL 30ng/mL L- 0.3
 : 1 - ; 1ng/mL 50ng/mL L- 0.6 : 1
 L- . AVA
 , pH pH 7.4 6.8
 6.0-7.0 pH

[0029]

AVB , 500 : 1 L-
 L- 2ng/mL 120ng/mL ,
 5-300ng/L . 1ng/mL 90ng/mL L- 1
 : 1 L- , L- L- ; 1ng/mL~ 75ng/mL L-
 1.4 : 1 ; 0.5ng/mL~ 30ng/mL L-
 0.3 : 1 ; 1ng/mL~ 50ng/mL L- 0.7 : 1
 L- . AVB
 , pH pH 7.4 6.8

[0030]

(AVC)

AVC Q 01-10 %
 , 1-15 % , 1-15 % , 1-15 % , 1-15 % , 1-15 %
 , 1-15 % , 1-15 % 25-75 % 3 -2 6
 AVC

[0031]

AVC	
	%
L-	7.0
	7.0
L-	7.0
	0.00
L-	7.0
L-	7.0
L-	7.6
L-	7.0
(B ₂)	1.4
3 -2 6	49.0

[0032]

AVA AVB AVC (15-30)

[0033]

[0034]

4000ng/kg/d() 7ng/kg/d()
 1000ng/kg/d

[0035]

AVA AVB
 AVC , (gel caps)

[0036]

[0037]

[0038]

[0039]

[0040]

[0041]

[0042]

[0043]

[0044]

(sluggi ng) , (pressi ng)

(sl ug)

[0045]

(shellac)

[0046]

P. F.

[0047]

[0048]

[0049]

B

[0050]

(single-channel infusion pump) IV (catheter)
(single-lumen) (Broviac), (Groshong),

[0051]

16

[0052]

1

[0053]

0.2ml (skin test) , 30
10ml 50ml/

[0054]

30 , 50ml 100ml/ 15

[0055]

50ml , 30 , 440ml 250ml/
(500ml (IV bag)). 15
1 , 30

[0056]

2

[0057]

1 , 500ml 250ml/
, 30

[0058] , 500nh 250nh/
30

[0059] 3

[0060] 2 1000nh , 1000nh 250nh/
1 , 30

[0061] 4 16

[0062] 1

[0063] 0.2nh , 30
10nh 50nh/

[0064] 30 , 50nh 100nh/ 15

[0065] 50nh , 30 440nh ,
, 100nh/ 200nh/

[0066] , 15 , 1 , 30

[0067]

()	(nh/)
4-7	100
7-10	150
10-16	200

[0068] 2

[0069] , 1 , 500nh ,
30

[0070] 10 , 500nh
200nh/ , 500nh

[0071] 3

[0072] 2 500nh , 500nh 1000nh
, 1 ,
30

[0073] , ,

(Hdgki n' s)

[0074]

(case history)
AVA AVB

[0075]

1

[0076]

AVA 53

[0077]

6 L- (, AVA) ,

[0078]

S 53

[0079]

AVA 5- 1 (5-
FU 52

[0080]

AVA (, ,)
CT (scan)

[0081]

AVA

[0082]

2

[0083]

AVA 70

[0084]

6 L- (, AVA) ,

[0085]

70 (,) ,
5-FU 9
(tanoxifen) 2
(nodule) (Taxoi)
21 CT 3
AVA

[0086]

2 14
5-Fu

[0087]

CT (scan) ; 3
(baseline)

[0088]

AVA

[0089]

AVA

5-FU

(maintenance)

[0090]

3

[0091]

AVA

52

[0092]

6

L-

(AVA)

[0093]

6

52

CHP(Combination of Cyclophosphamide, Doxorubicin/hydroxydoxorubicin, and Vincristine along with the corticosteroid Prednisolone)

CT

AVA

AVA

4

[0094]

-A

[0095]

5

5

(Rituxan)

[0096]

4

[0097]

AVB

72

[0098]

6

L-

(AVB)

[0099]

72

3

5-Fu

AVB

[0100]

AVB

11

AVB

CT

CT

[0101]

[0102]